Drug-induced acneiform eruption

American Journal of Clinical Dermatology

Volumn 12, Issue 4, 2011, Pages 233-245

  Du Thanh, Aurélie ^a   Kluger, Nicolas ^a   Bensalleh, Houdna ^a   Guillot, Bernard ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Acne; Anabolic steroids; Antiepileptic drugs; Antituberculars; Aripiprazole; Ciclosporin; Corticosteroids; Corticotropin; Cytostatics; Dactinomycin; Epidermal growth factor inhibitors; Epidermal growth factor receptor antagonists; Ethionamide; fms like tyrosine kinase 3 inhibitors; Halogens; Histone deacetylase inhibitors; Hormonal contraceptives; Immunomodulators; Iodine; Isoniazid; Lithium; Proteasome inhibitors; Rifampicin; Serotonin uptake inhibitors; Sirolimus; Testosterone congeners; Tricyclic antidepressants; Tumour necrosis factor inhibitors; Vascular endothelial growth factor inhibitors; Vitamin B12 analogues

Indexed keywords

AMINEPTINE; ANDROGEN; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; AZATHIOPRINE; CONTRACEPTIVE AGENT; CORTICOSTEROID; CORTICOTROPIN; CYANOCOBALAMIN; CYCLOSPORIN; DACTINOMYCIN; DANAZOL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HALOGEN; IMIPRAMINE; IMMUNOMODULATING AGENT; ISONIAZID; LITHIUM; MAPROTILINE; PIMECROLIMUS; PYRIDOXINE; RAPAMYCIN; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; THIAMINE; THIOURACIL; THIOUREA; THYROTROPIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ACNE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HORMONAL CONTRACEPTION; HUMAN; MEDICAL STAFF; PRIORITY JOURNAL; REVIEW;

ACNEIFORM ERUPTIONS; AGE OF ONSET; DRUG ERUPTIONS; DRUG RESISTANCE; HUMANS;

EID: 79958830523     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11588900-000000000-00000     Document Type: Review

References (140)

1. Hitch JM. Acneform eruptions induced by drugs and chemicals. JAMA 1967; 200: 879-80
2. Kligman AM, Plewig G. Classification of acne. Cutis 1976; 17: 520-2
3. Brunner MS, Riddell Jr JM, Best WR. Cutaneous side effects of ACTH, cortisone, and pregnenolone therapy. J Invest Dermatol 1951; 16: 205-9
4. Sullivan M, Zeligman I. Acneform eruption due to corticotropin. AMA Arch Dermatol 1956; 73: 133-41
5. Plewig G, Kligman AM. Induction of acne by topical steroids. Arch Dermatol Forsch 1973; 247: 29-52
6. Fung MA, Berger TG. A prospective study of acute-onset steroid acne associated with administration of intravenous corticosteroids. Dermatology 2000; 200: 43-4 (Pubitemid 30088335)
7. Monk B, Cunlife WJ, Layton AM, et al. Acne induced by inhaled corticosteroids. Clin Exp Derm 1993; 1: 148-50 (Pubitemid 23098403)
8. Guillot B. Adverse skin reactions to inhaled corticosteroids. Expert Opin Drug Saf 2002; 1: 325-9
9. Bedane C, Souyri N. Induced acne. Ann Dermatol Venereol 1990; 117: 53-8 (Pubitemid 20088418)
10. Hurwitz RM. Steroid acne. J Am Acad Dermatol 1989; 21: 1179-81 (Pubitemid 20216984)
11. Fyrand O, Fiskaadal HJ, Trygstad O. Acne in pubertal boys undergoing treatment with androgens. Acta Derm Venereol 1992; 72: 148-9
12. Heydenreich G. Testosterone and anabolic steroids and acne fulminans. Arch Dermatol 1989; 125: 571-2
13. Melnik B, Jansen T, Grabbe S. Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem. J Dtsch Dermatol Ges 2007; 5: 110-7 (Pubitemid 46212727)
14. Gerber PA, Kukova G, Meller S, et al. The dire consequences of doping. Lancet 2008; 372: 1544
15. Yildizbas B, Sahin HG, Kolusari A, et al. Side effects and acceptability of Implanon: a pilot study conducted in eastern Turkey. Eur J Contracept Reprod Health Care 2007; 12: 248-52 (Pubitemid 47347168)
16. Funk S, Miller MM, Mishell Jr DR, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71: 319-26 (Pubitemid 40602307)
17. Gezginc K, Balci O, Karatayli R, et al. Contraceptive efficacy and side effects of Implanon. Eur J Contracept Reprod Health Care 2007; 12: 362-5 (Pubitemid 350146716)
18. Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009; 91: 1646-53
19. Cohen EB, Rossen NN. Acne vulgaris in connection with the use of progestagens in a hormonal IUD or a subcutaneous implant [in Dutch]. Ned Tijdschr Geneeskd 2003; 147: 2137-9 (Pubitemid 37328286)
20. Ilse JR, Greenberg HL, Bennett DD. Levonorgestrel-releasing intrauterine system and new-onset acne [letter]. Cutis 2008; 82: 158
21. Greenberg RD. Acne vulgaris associated with antigonadotropic (Danazol) therapy. Cutis 1979; 24: 431-3
22. Thioly-Bensoussan D, Charpentier A, Triller R, et al. Iatrogenic acne caused by amineptin (Survector): apropos of 8 cases. Ann Dermatol Venereol 1988; 115: 1177-80 (Pubitemid 19062122)
23. Grupper C. New iatrogenic acne: acne caused by amineptin (Survector).Ann Dermatol Venereol 1988; 115: 1174-6 (Pubitemid 19062121)
24. Vexiau P, Gourmel B, Husson C, et al. Severe lesions of acne type induced by chronic amineptin poisoning: apropos of 6 cases. Ann Dermatol Venereol 1988; 115: 1180-2 (Pubitemid 19062123)
25. Teillac D, Weber MJ, Lowenstein W, et al. Acne caused by Survector [in French]. Ann Dermatol Venereol 1988; 115: 1183-4
26. LévigneV, FaisantM,Mourier CG, et al. Monstrous acne in the adult: inducerrole of Survector? Ann Dermatol Venereol 1988; 115: 1184-5
27. Vexiau P, Gourmel B, Julien R, et al. Severe acne-like lesions caused by amineptine overdose [letter]. Lancet 1988; 1: 585 (Pubitemid 18060499)
28. Vexiau P, Gourmel B, Castot A, et al. Severe acne due to chronic amineptine overdose. Arch Dermatol Res 1990; 282: 103-7 (Pubitemid 20145495)
29. Huet P, Dandurand M, Joujoux JM, et al. Acne induced by amineptin: adnexal toxiderma. Ann Dermatol Venereol 1996; 123: 817-20
30. Duriot JF, Dutertre JP, Grenier JM, et al. Amineptin dependence and iatrogenic acne: review of the literature apropos of a case. Ann Med Psychol (Paris) 1991; 149: 795-7
31. Farella V, Sberna F, Knöpfel B, et al. Acne-like eruption caused by amineptine. Int J Dermatol 1996; 35: 892-3
32. Bettoli V, Trimurti S, Lombardi AR, et al. Acne due to amineptine abuse. J Eur Acad Dermatol Venereol 1998; 10: 281-3
33. Grimalt R, Mascaró -Galy JM, Ferrando J, et al. Guess what? Macronodular iatrogenic acne due to amineptine. Eur J Dermatol 1999; 9: 491-2 (Pubitemid 29475983)
34. De Gá lvez Aranda MV, Sá nchez PS, Alonso Corral MJ, et al. Acneiform eruption caused by amineptine: a case report and review of the literature. J Eur Acad Dermatol Venereol 2001; 15: 337-9 (Pubitemid 33014847)
35. Ponte CD. Maprotiline induced acne. Am J Psychiatry 1982; 139: 141
36. Ossofsky J. Amenorrhea in endogenous depression. Int Pharmacopsychiatry 1974; 9: 100-8
37. Kusumi Y. A cutaneous side effect of lithium: report of two cases. Dis Nerv Syst 1971; 32: 853-4
38. Ruíz-Maldonado R, Pérez de Francisco C, Tamayo L. Lithium dermatitis [letter]. JAMA 1973; 224: 1534
39. Yoder FW. Acneiform eruption due to lithium carbonate [letter]. Arch Dermatol 1975; 111: 396-7
40. Sarantidis D, Waters B. A review and controlled study of cutaneous conditions associated with lithium carbonate. Br J Psychiatry 1983; 143: 42-50 (Pubitemid 13057763)
41. Yeung CK, Chan HH. Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol 2004; 5: 3-8 (Pubitemid 38316537)
42. Heng MC. Lithium carbonate toxicity: acneiform eruption and other manifestations. Arch Dermatol 1982; 118: 246-8 (Pubitemid 12142604)
43. Jenkins RB, Ratner AC. Diphenyl hydantoin and acne [letter]. N Engl J Med 1972; 287: 148
44. Frentz G. Acne and phenytoin [in Danish]. Ugeskr Laeger 1977; 139: 338-9
45. Norris JF, Cunliffe WJ. Phenytoin-induced gum hypertrophy improved by isotretinoin. Int J Dermatol 1987; 26: 602-3 (Pubitemid 17160091)
46. Gunwald MH, Ben-Dor D, Livni E, et al. Acne keloidalis-like lesions on the scalp associated with antiepileptic drugs. Int J Dermatol 1990; 29: 559-61 (Pubitemid 20345106)
47. Nielsen JN, Licht RW, Fogh K. Two cases of acneiform eruption associated with lamotrigine. J Clin Psychiatry 2004; 65: 1720-2
48. Hesse S, Berbis P, Lafforgue P, et al. Acne and enthesiopathy during antiepileptic treatment. Ann Dermatol Venereol 1992; 119: 655-8
49. Greenwood R, Fenwick PB, Cunliffe WJ. Acne and anti-convulsants. BrMed J 1983; 287: 1669-70
50. Mishra B, Praharaj SK, Prakash R, et al. Aripiprazole-induced acneiform eruption. Gen Hosp Psychiatry 2008; 30: 479-81
51. Warnock JK, Morris DW. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol 2002; 3: 329-39 (Pubitemid 34753686)
52. Ade G. Poussées d'eczéma séborrhéique ou acné iforme probablement consécutives à un traitement à la vitamine B12 [letter]. Dermatologica 1958; 116: 366
53. Dugois P, Amblard P, Imbert R, et al. Acne due to vitamin B12 [in French]. Bull Soc Fr Dermatol Syphiligr 1969; 76: 382-3
54. Puissant A, Vanbremeersch F, Monfort J, et al. A new iatrogenic dermatosis: acne caused by vitamin B12 [in French]. Bull Soc Fr Dermatol Syphiligr 1967; 74: 813-5
55. Dupré A, Albarel N, Bonafe JL, et al. Vitamin B-12 induced acnes.Cutis 1979; 24: 210-1
56. Sheretz EF. Acneiform eruption due to 'megadose' vitamins B6 and B12 Cutis 1991; 48: 119-20
57. Braun-Falco O, Lincke H. The problem of vitamin B6/B12 acne: a contribution on acne medicamentosa. MMW Munch Med Wochen Schr 1976; 118: 155-60
58. Blatt J, Lee PA. Severe acne and hyperandrogenemia following dactinomycin. Med Pediatr Oncol 1993; 5: 373-4 (Pubitemid 23152977)
59. Schmoeckel C, von Liebe V. Acneiformexanthema caused by azathioprine [in German]. Hautarzt 1983; 34: 413-5
60. Bencini PL, Montagnino G, Crosti C, et al. Cutaneous lesion in 67 yclosporin- treated renal transplant recipients. Dermatologica 1986; 172: 24-30 (Pubitemid 16127742)
61. Strahan JE, Burch JM. Cyclosporine-induced infantile nodulocystic acne. Arch Dermatol 2009; 145: 797-9
62. Richter A, Beideck S, Bender W, et al. Epidermal cysts and folliculitis caused by cyclosporin A [in German]. Hautarzt 1993; 44: 521-3 (Pubitemid 23252851)
63. el-Shahawy MA, Gadallah MF, Massry SG. Acne: a potential side effect of cyclosporine A therapy. Nephron 1996; 72: 679-82
64. Carnero L, Silvestre JF, Guijarro J, et al. Nuchal acne keloidalis associated with cyclosporin. Br J Dermatol 2001; 144: 429-30 (Pubitemid 32178842)
65. Bunker CB, Rustin MH, Dowd PM. Isotretinoin treatment of severe acne in posttransplant patients taking cyclosporine. J Am Acad Dermatol 1990; 22: 693-4 (Pubitemid 20134720)
66. Abel EA. Isotretinoin treatment of severe cystic acne in a heart transplant patient receiving cyclosporine: consideration of drug interactions [letter]. J Am Acad Dermatol 1991; 24: 511
67. Hazen PE, Walker AE, Stewart JJ, et al. Successful use of isotretinoin in a patient on cyclosporine: apparent lack of toxicity [letter]. Int J Dermatol 1993; 32: 466 (Pubitemid 23189902)
68. Mahé E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol 2006; 55: 139-42 (Pubitemid 43867022)
69. Mahé E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79: 476-82 (Pubitemid 40280181)
70. Lü bbe J, SorgO,Malé PJ, et al. Sirolimus-induced inflammatory papuleswith acquired reactive perforating collagenosis. Dermatology 2008; 216: 239-42
71. Bakos L, Bakos RM. Focal acne during topical tacrolimus therapy for vitiligo. Arch Dermatol 2007; 143: 1223-4 (Pubitemid 47443398)
72. Li JC, Xu AE. Facial acne during topical pimecrolimus therapy for vitiligo. Clin Exp Dermatol 2009; 34: e489-90
73. Bereston ES. Reactions to antituberculous drugs. J Invest Dermatol 1959; 33: 427-39
74. Cohen LK, George W, Smith R. Isoniazid-induced acne and pellagra: occurrence in slow inactivators of isoniazid. Arch Dermatol 1974; 109: 377-81
75. Oliwiecki S, Burton JL. Severe acne due to isoniazid. Clin ExpDermatol 1988; 13: 283-4
76. Holdiness MR. Adverse cutaneous reactions to antituberculosis drugs. Int J Dermatol 1985; 24: 280-5 (Pubitemid 15062922)
77. Hesse PG. Antitubercular therapy and acneiform exanthema [in German]. Dermatol Wochenschr 1966; 152: 305-12
78. Nwokolo U. Acneiform lesions in combined rifampicin treatment in Africans [letter]. Br Med J 1974; 3: 473
79. Levantine A, Almeyda J. Cutaneous reactions to antituberculosis drugs. Br J Dermatol 1972; 86: 651-5
80. Papa CM. Acne and hidden iodides. Arch Dermatol 1976; 112: 55-6
81. Rosenberg FR, Einbinder J, Walzer RA, et al. Vegetating iododerma: an immunologic mechanism. Arch Dermatol 1972; 105: 900-5
82. Inman P. Proceedings: iododerma. Br J Dermatol 1974; 91: 709-11
83. Kint A, Van Herpe L. Iododerma. Dermatologica 1977; 155: 171-3
84. Heydenreich G, Larsen PO. Iododerma after high dose urography in an oliguric patient. Br J Dermatol 1977; 97: 567-9 (Pubitemid 8214662)
85. Belaïch S, Crickx B, Schwartz C, et al. Vegetating iododerma following lymphography. Ann Dermatol Venereol 1985; 112: 699-700
86. Wilkin JK, Strobel D. Iododerma occurring during thyroid protection treatment. Cutis 1985; 36: 335-7 (Pubitemid 16226347)
87. Boudoulas O, Siegle RJ, Grimwood RE. Iododerma occurring after orally administered iopanoic acid. Arch Dermatol 1987; 123: 387-8 (Pubitemid 17024682)
88. Soria C, Allegue F, Españ a A, et al. Vegetating iododerma with underlying systemic diseases: report of three cases. J Am Acad Dermatol 1990; 22: 418-22 (Pubitemid 20212393)
89. Vaillant L, Pengloan J, Blanchier D, et al. Iododerma and acute respiratory distress with leucocytoclastic vasculitis following the intravenous injection of contrast medium. Clin Exp Dermatol 1990; 15: 232-3 (Pubitemid 20164909)
90. Noonan MP, Williams CM, Elgart ML. Fungating pustular plaques in a patient with Graves' disease: iododerma. Arch Dermatol 1994; 130: 786-7, 789-90
91. Alpay K, Kurkcuoglu N. Iododerma: an unusual side effect of iodide ingestion. Pediatr Dermatol 1996; 13: 51-3 (Pubitemid 26064253)
92. Ricci C, Krasovec M, Frenk E. Amiodarone induced iododerma treated by cyclosporine. Ann Dermatol Venereol 1997; 124: 260-3 (Pubitemid 27204725)
93. Miranda-Romero A, Sá nchez-Sambucety P, Esquivias Gó mez JI, et al. Vegetating iododerma with fatal outcome. Dermatology 1999; 198: 295-7 (Pubitemid 29281422)
94. Pranteda G, Grimaldi M, Salzetta M, et al. Vegetating iododerma and pulmonary eosinophilic infiltration: a simple co-occurrence? Acta Derm Venereol 2004; 84: 480-1 (Pubitemid 40126074)
95. Paul AK, Al-Nahhas A, Ansari SM, et al. Skin eruptions following treatment with iodine-131 for hyperthyroidism: a rare and un-reported early/ intermediate side effect. Nucl Med Rev Cent East Eur 2005; 8: 125-7 (Pubitemid 43115963)
96. Aydingö z IE, Gö ktay F, Serdar ZA, et al. Iododerma following sitz bath with povidone-iodine. Australas J Dermatol 2007; 48: 102-4 (Pubitemid 46802050)
97. Massé M, Falanga V, Zhou LH. Use of topical povidone-iodine resulting in an iododerma-like eruption. J Dermatol 2008; 35: 744-7
98. Arditti J, Follana J, Bonerandi JJ, et al. Bromide vegetating skin diseases after treatment by a bromocalcic specialty. Eur J Toxicol Environ Hyg 1976; 9: 59-63
99. Smith SZ, Scheen SR. Bromoderma. Arch Dermatol 1978; 114: 458-9 (Pubitemid 8324624)
100. Roman P, Bourgeois-Droin C. Bromide-induced skin diseases. AnnDermatol Venereol 1999; 126: 831-4
101. Maffeis L, Musolino MC, Cambiaghi S. Single-plaque vegetating romoderma. J Am Acad Dermatol 2008; 58: 682-4
102. Herxheimer K. Uber chlorakne [letter]. Mü nchener Medicinische Wochenschrift 1899; 46: 278
103. Tindall JP. Chloracne and chloracnegens. J AmAcadDermatol 1985; 13: 539-58 (Pubitemid 15246634)
104. McDonagh AJG, Gawkrodger DJ, Walker AE. Chloracne. Clin Exp Dermatol 1993; 18: 523-5
105. Rodríguez-Pichardo A, Camacho F. Chloracne as a consequence of a family accident with chlorinated dioxins [letter]. J Am Acad Dermatol 1990; 22: 1121 (Pubitemid 20186147)
106. SoperLE, Vitez TS,Weinberg D.Metabolism of halogenated anaesthetic agents as a possible cause of acneiform eruptions. Anaesth Analg 1973; 52: 125-7
107. Guldager H. Halothane allergy as a cause of acne. Lancet 1987; 1: 1211-2
108. Alagheband M, Engineer L. Lithium and halogenoderma. Arch Dermatol 2000; 136: 126-7
109. Joynt RL. Dantrolene sodium: long term effects in patients with muscle spasticity. Arch Phys Med Rehabil 1976; 57: 212-7
110. Pembrocke AC, Sexena SR, Katiara M, et al. Acne induced by dantrolene. Br J Dermatol 1981; 104: 465-8
111. Mowbray M, Sinclair SA,Allan SJ. Severe acneiform eruption exacerbated by dantrolene sodium. Clin Exp Dermatol 2009; 34: 248-9
112. Burkhart CG. Quinidine-induced acne. Arch Dermatol 1981; 117: 603-4 (Pubitemid 11022579)
113. Scott C, Staughton RC, Bunker CJ, et al. Acne vulgaris and acne rosacea as part of immune reconstitution disease in HIV-1 infected patients starting antiretroviral therapy. Int J STD AIDS 2008; 19: 493-5
114. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235-46 (Pubitemid 46224035)
115. Busam KJ, Capoiece P, Motzer R, et al. Cutaneous side effects in cancer patients treated with the anti-epidermal growth factor receptor antibody C 225 Br J Dermatol 2001; 144: 1169-76 (Pubitemid 34204207)
116. Walon L, Gilbeau C, Lachapelle JM. Acneiform eruptions induced by cetuximab. Ann Dermatol Venereol 2003; 130: 443-6 (Pubitemid 36723277)
117. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151: 238-41 (Pubitemid 39061311)
118. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today 2005; 41: 107-27 (Pubitemid 40461533)
119. Hannoud S, Rixe O, Bloch J, et al. Skin signs associated with epidermal growth factor inhibitors. Ann Dermatol Venereol 2006; 133: 239-42 (Pubitemid 44030153)
120. Segaert S, Van Custem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33 (Pubitemid 41222414)
121. Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on longterm treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009; 161: 515-21
122. U.S. Department of Health and Human Services, National Institutes of Health,National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 40 published 28 May 2009; version 403 published 14 June 2010 [online]. Available from URL: CTCAE/CTCAE-403-2010-06-14-QuickReference-5x7pdf [Accessed 2011 Apr 6]
123. Scope A, Agero AL, Dusza AL, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25: 5390-6 (Pubitemid 350232214)
124. Deplanque G. CYTAR: a randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients [abstract no. 9019]. ASCO Annual Meeting; 2010 Jun 4-8; Chicago (IL)
125. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61: 912-20 (Pubitemid 44024887)
126. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803-12 (Pubitemid 44450468)
127. Martín JM, Jordá E, Monteagudo C, et al. Follicular acneiform eruption induced by imatinib. J Eur Acad Dermatol Venereol 2006; 20: 1368-70 (Pubitemid 44614666)
128. Fleta-AsínB,Vañ ó -Galván S, Ledo-Rodríguez A, et al. Facial acneiform rash associated with sorafenib [letter]. Dermatol Online J 2009; 15: 7
129. Porta C, Paglino C, Imarisio I, et al. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007; 7: 127-34
130. Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 2007; 32: 71-4 (Pubitemid 46006373)
131. LeeWJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045-51
132. Nardone B, Nicholson K, Newman M, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res 2010; 16: 4452-60
133. Michot C, Guillot B, Dereure O. Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents. Dermatology 2010; 220: 49-50
134. Keenan BP, AbuavR.Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme [letter]. Arch Dermatol 2010; 146: 577
135. Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010; 16: 1613-23
136. Bassi E, Poli F, Charachon A, et al. Infliximab-induced acne: report of two cases. Br J Dermatol 2007; 156: 402-3 (Pubitemid 46095989)
137. Sladden MJ, Clarke PJ, Mitchell B. Infliximab-induced acne: report of a third case [letter]. Br J Dermatol 2008; 158: 172 (Pubitemid 350221885)
138. Sun G, Wasko CA, Hsu S. Acneiform eruption following anti-TNF-alpha treatment: a report of three cases. J Drugs Dermatol 2008; 7: 69-71
139. Ree AH, Dueland S, Folkvord S, et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 2010; 11: 459-64
140. Pour L, Hajek R, Zdenek A, et al. Skin lesions induced by bortezomib. Haematologica 2005; 90 (12 Suppl.): ECR44